Phase 1/2 Study of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin's Lymphoma

Trial Profile

Phase 1/2 Study of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin's Lymphoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Glycopyranosyl lipid adjuvant (Primary) ; Pembrolizumab
  • Indications Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Immune Design
  • Most Recent Events

    • 06 Jun 2017 Results (n=21 as of 31 Dec 2016) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2017 Results published in an Immune Design media release.
    • 17 May 2017 According to an Immune Design media release, the company intends to submit follow-up data from all patients in both the Phase 1 dose escalation and Phase 2 randomized portions of the study for presentation at the American Society of Hematology Annual Meeting in December 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top